capecitabine

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Thymidylate synthase inhibitor

Related drugs:

No biomarker	Colon Cancer	No biomarker	Colon Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	docetaxel + capecitabine Sensitive: A1 - Approval docetaxel + capecitabine Sensitive : A1	docetaxel + capecitabine Sensitive: A1 - Approval docetaxel + capecitabine Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
No biomarker	Oral Cancer	No biomarker	Oral Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	paclitaxel + capecitabine Sensitive: A2 - Guideline paclitaxel + capecitabine Sensitive : A2	paclitaxel + capecitabine Sensitive: A2 - Guideline paclitaxel + capecitabine Sensitive : A2
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Penile Cancer	No biomarker	Penile Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	5-fluorouracil + capecitabine Sensitive: A2 - Guideline 5-fluorouracil + capecitabine Sensitive : A2	5-fluorouracil + capecitabine Sensitive: A2 - Guideline 5-fluorouracil + capecitabine Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	gemcitabine + capecitabine Sensitive: A2 - Guideline gemcitabine + capecitabine Sensitive : A2	gemcitabine + capecitabine Sensitive: A2 - Guideline gemcitabine + capecitabine Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	temozolomide + capecitabine Sensitive: A2 - Guideline temozolomide + capecitabine Sensitive : A2	temozolomide + capecitabine Sensitive: A2 - Guideline temozolomide + capecitabine Sensitive : A2
No biomarker	Small Intestinal Carcinoma	No biomarker	Small Intestinal Carcinoma	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Gallbladder Cancer	No biomarker	Gallbladder Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	docetaxel + capecitabine Sensitive: A2 - Guideline docetaxel + capecitabine Sensitive : A2	docetaxel + capecitabine Sensitive: A2 - Guideline docetaxel + capecitabine Sensitive : A2
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	capecitabine + oxaliplatin Sensitive: A2 - Guideline capecitabine + oxaliplatin Sensitive : A2	capecitabine + oxaliplatin Sensitive: A2 - Guideline capecitabine + oxaliplatin Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	capecitabine + oxaliplatin Sensitive: A2 - Guideline capecitabine + oxaliplatin Sensitive : A2	capecitabine + oxaliplatin Sensitive: A2 - Guideline capecitabine + oxaliplatin Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	gemcitabine + capecitabine Sensitive: A2 - Guideline gemcitabine + capecitabine Sensitive : A2	gemcitabine + capecitabine Sensitive: A2 - Guideline gemcitabine + capecitabine Sensitive : A2

capecitabine

Associations
(81)

Associations
(81)

capecitabine

Associations(81)

Associations(81)

Associations
(81)

Associations
(81)